Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Up 3.0 %

LPCN opened at $5.15 on Friday. Lipocine has a twelve month low of $2.38 and a twelve month high of $11.79. The company has a 50-day moving average price of $5.10 and a 200 day moving average price of $5.64. The company has a market cap of $27.55 million, a PE ratio of -6.78 and a beta of 1.18.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, sell-side analysts expect that Lipocine will post -0.78 earnings per share for the current year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.